Neuroleptic malignant syndrome in patients with COVID-19

We report the first two cases of Coronavirus Disease 2019 (COVID-19) who were receiving intensive care including favipiravir, and were clinically diagnosed with neuroleptic malignant syndrome (NMS) to focus attention on NMS in COVID-19 management. Case 1: A 46-year-old-man with acute respiratory dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Soh, Mitsuhito, Hifumi, Toru, Isokawa, Shutaro, Shimizu, Masato, Otani, Norio, Ishimatsu, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242930/
https://www.ncbi.nlm.nih.gov/pubmed/32473756
http://dx.doi.org/10.1016/j.ajem.2020.05.042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242930/
https://www.ncbi.nlm.nih.gov/pubmed/32473756
http://dx.doi.org/10.1016/j.ajem.2020.05.042

Ejemplares similares